Apalutamide - An Oral Androgen Receptor Inhibitor for Non-Metastatic CRPC

An application has been made to the FDA for apalutamide, a possible hormonal treatment for men who are castrate resistant, but not yet metastatic.

Xtandi Improves Metastasis Free Survival In Men Who Are Castrate Resistant And Do Not Have Metastasis

It was announced that Enzalutamide (Xtandi) is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in men who have castrate resistant prostate cancer but do not have any confirmed metastases.